RxDoctor Payments Data

Chifoo Yue, MD

Internal Medicine · Cypress, CANPI 1952374100

Payments from drug & device makers

$6,448in general payments, 2019–2025

Across 357 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$900
  • Lilly USA, LLC$843
  • Boehringer Ingelheim$751
  • Amgen$456
  • Bayer$360
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,28197%
  • Education$1663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,448 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$140,797
Medicare patients
203
Services billed
3,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$62,209
JardianceEmpagliflozin48$59,144
LinzessLinaclotide50$54,097
XareltoRivaroxaban42$51,386
FarxigaDapagliflozin Propanediol50$49,066
KerendiaFinerenone37$45,666
ProliaDenosumab26$44,016
Cinacalcet Hcl28$42,295
OzempicSemaglutide32$42,239
TrulicityDulaglutide26$39,685
TradjentaLinagliptin43$35,510
EliquisApixaban22$26,738
EntrestoSacubitril/Valsartan23$24,854
MounjaroTirzepatide11$21,474
VemlidyTenofovir Alafenamide15$20,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr$751$129,312128 claims
GSKTrelegy Ellipta, Anoro Ellipta$123$69,31098 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,216$61,91671 claims
Lilly USA, LLCTrulicity, Mounjaro$843$61,15937 claims
AbbVieLinzess$237$54,09750 claims
Johnson & JohnsonXarelto$205$51,38642 claims
BayerKerendia$360$45,66637 claims
AmgenProlia$456$44,01626 claims
Novo NordiskOzempic$900$42,23932 claims
PfizerEliquis$314$26,73822 claims
NovartisEntresto$16$24,85423 claims
GileadVemlidy$169$20,34415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Cypress

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →